Comparison · NCT02424851-a16e9bcf
Arm A (BBD) vs Arm B (BTD): Number of Participants With >50% Reduction From Baseline in Serum Free Light Chain
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A (BBD) vs Arm B (BTD): Number of Participants With >50% Reduction From Baseline in Serum Free Light Chain. Trial comparisons, record NCT02424851-a16e9bcf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02424851-a16e9bcf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.813 | 0.57 | 0.934 | wilson | |
| Risk in group 2 | 0.214 | 0.0757 | 0.476 | wilson | |
| Risk difference, group 1 minus group 2 | 0.598 | 0.241 | 0.783 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.79 | 1.35 | 10.6 | log | |
| Odds ratio, group 1 over group 2 | 15.9 | 2.65 | 95.2 | log | |
| Number needed to treat, for one more participant with the outcome on Arm A (BBD) than on Arm B (BTD) | 1.67 | 1.28 | 4.14 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A (BBD) | Bortezomib, Bendamustine and Dexamethasone~Bortezomib: 1.3 mg/m2 subcutaneously\* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~\*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib~Bendamustine: 60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)~Dexamethasone: 40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle | 13 | 16 | OG000 |
| Group 2 | Arm B (BTD) | Thalidomide, Bendamustine and Dexamethasone~Thalidomide: 100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)~Bendamustine: 60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)~Dexamethasone: 40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle | 3 | 14 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With >50% Reduction From Baseline in Serum Free Light Chain
- Description
- Time frame
- End of week 6 (after receiving two cycles of therapy)
- Population
- The primary endpoint of serum free light chain response was assessed in 30 patients where samples were available at screening and the end of two cycles of trial treatment.
Source ClinicalTrials.gov
Trial
- Title
- Optimising Renal Outcome in Myeloma Renal Failure
- NCT number
- NCT02424851
- Phases
- PHASE2
- Conditions
- Multiple Myeloma, Chronic Kidney Disease
- Interventions
- Bortezomib, Thalidomide, Bendamustine, Dexamethasone
- Lead sponsor
- Oxford University Hospitals NHS Trust
- Results first posted
- 2022-01-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02424851?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02424851-a16e9bcf